BiotechTube
Intellia Therapeutics

Intellia Therapeutics

NTLAPhase 3
Cambridge, United StatesFounded 2014450-550 employeesintelliatx.com

Intellia Therapeutics is a pioneer in the development of CRISPR/Cas9-based therapeutics, aiming to cure severe genetic and other diseases through precise genome editing. The company has achieved significant milestones, including the first-ever clinical data demonstrating in vivo CRISPR genome editing in humans. Its strategy leverages a dual-platform approach, developing both in vivo (systemically administered) and ex vivo (cell-based) therapies, with key partnerships including Regeneron and Novartis to advance its pipeline.

Market Cap
$1.5B
+37.9% period
Pipeline
4
1 in Phase 3
Patents
13
granted
Publications
20
indexed

NTLA · Stock Price

USD 12.84+3.53 (+37.92%)

Historical price data

AI Company Overview

Intellia Therapeutics is a pioneer in the development of CRISPR/Cas9-based therapeutics, aiming to cure severe genetic and other diseases through precise genome editing. The company has achieved significant milestones, including the first-ever clinical data demonstrating in vivo CRISPR genome editing in humans. Its strategy leverages a dual-platform approach, developing both in vivo (systemically administered) and ex vivo (cell-based) therapies, with key partnerships including Regeneron and Novartis to advance its pipeline.

Genetic DiseasesOncologyAutoimmune DiseasesRare Diseases

Technology Platform

Modular CRISPR/Cas9 genome editing platform enabling both in vivo (via lipid nanoparticle delivery) and ex vivo (cell therapy) therapeutic approaches to precisely edit disease-causing genes.

Pipeline

4
4 drugs in pipeline1 in Phase 3
DrugIndicationStageWatch
NTLA-2002 + Normal Saline IV AdministrationHereditary AngioedemaPhase 3
Biological NTLA-3001Lung DiseasePhase 1/2
Biological NTLA-2002Hereditary AngioedemaPhase 1/2
NTLA-2001Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyPhase 1

Funding History

4
Total raised:$468M
Follow-on Offering$275MJun 15, 2021
IPO$108MMay 6, 2016
Series B$70MMay 15, 2015
Series A$15MNov 15, 2014

Opportunities

Intellia's primary growth opportunities include successfully commercializing its lead in vivo programs (NTLA-2001, NTLA-2002) in multi-billion dollar markets, expanding its ex vivo oncology pipeline, and leveraging its validated platform to initiate new programs in high-need genetic and autoimmune diseases.
The modular nature of its technology allows for rapid pipeline expansion.

Risk Factors

Key risks include clinical trial failures, safety concerns with novel genome editing, intense competition from other gene editing and traditional modalities, complex manufacturing scale-up, regulatory hurdles for first-in-class therapies, and ongoing intellectual property disputes in the CRISPR field.

Competitive Landscape

Intellia competes directly with other CRISPR leaders like CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics, as well as large pharma companies with alternative modalities. Its differentiation lies in its strong clinical proof-of-concept for in vivo editing, a balanced pipeline, and a powerful strategic and financial partnership with Regeneron.